Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/24/2015 03/25/2015 03/26/2015 03/27/2015 03/30/2015 Date
68.22(c) 62.39(c) 61.15(c) 63.37(c) 64.81(c) Last
2 605 144 5 379 860 5 755 075 4 336 080 2 638 226 Volume
-1.46% -8.55% -1.99% +3.63% +2.27% Change
More quotes
Financials ($)
Sales 2015 224 M
EBIT 2015 -82,5 M
Net income 2015 -99,5 M
Finance 2015 376 M
Yield 2015 -
Sales 2016 290 M
EBIT 2016 -45,3 M
Net income 2016 -65,8 M
Finance 2016 532 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 32,7x
EV / Sales 2016 24,8x
Capitalization 7 714 M
More Financials
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer.The company operates in two segments: Drug Discovery & Development and... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/23 ISIS PHARMACEUTICALS : Earns $9M for Advancing ISIS-SMN Rx in Infants With Spina..
03/23 ISIS PHARMACEUTICALS : Reports Positive Phase 1 Data on Isis-ANGPTL3Rx
03/19 ISIS PHARMACEUTICALS : Cold Spring Harbor Laboratory, Isis Pharmaceuticals Assig..
03/18 INTERLEUKIN GENETICS : Expands its Collaboration with Isis Pharmaceuticals for G..
03/06 ISIS PHARMACEUTICALS : Earns $15 Million From GSK for Advancing ISIS-TTR Rx
03/06 ISIS PHARMACEUTICALS : Earns $9M for Advancing ISIS-SMN Rx in Infants With Spina..
03/02 Isis Reports Financial Results and Highlights for 2014
More news
Sector news : Biotechnology & Medical Research - NEC
03/30 PUMA BIOTECHNOLOGY : NYSE stocks posting largest percentage increases
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
03/26 Pfizer Is An Outright Buy - Cramer's Lightning Round (3/25/15)
03/17 PC Related Means Sell - Cramer's Lightning Round (3/16/15)
03/13 MasterCard Is At A Discount - Cramer's Lightning Round (3/12/15)
03/06 ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
03/06 Isis Pharma earns $9M milestone from Biogen


Comments 
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF